Sunscreening Agents Clinical Trial
Official title:
Determination of the Sun Protection Factor (SPF) and in Vitro UVA Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
NCT number | NCT03157583 |
Other study ID # | 207583 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 21, 2017 |
Est. completion date | July 7, 2017 |
Verified date | May 2019 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the SPF and UVAPF of four sunscreen formulations using international standard methodologies ISO24444:2010 for SPF and ISO24443:2012 for UVAPF.
Status | Completed |
Enrollment | 8 |
Est. completion date | July 7, 2017 |
Est. primary completion date | July 7, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form - Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination - Participants with a Fitzpatrick Skin Type of I, II or III - Participants with an Individual Typology Angle (ITA°) greater than 28° Exclusion Criteria: - Women who are known to be pregnant or who are intending to become pregnant over the duration of the study - Women who are breast-feeding or lactating - Participants having used medication with known photo-toxic and/or photosensitizing potential (e.g. hypericum perforatum, antibiotics, blood pressure regulating agents) up to 14 days prior to screening - Participants with a history of systemic therapy with anti-inflammatory agents or analgesics (e.g. diclofenac) up to 3 days prior to screening - Participants with dermatological conditions - Participants with a history of abnormal response to the sun - Participants having marks, blemishes or nevi or presenting existing sun damage in the test area - Participants having excessive hair, moles, tattoos, scars or other imperfections in the test area that could influence the investigation - Participants with a history of systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. anti-allergics) up to 7 days prior to screening - Participants with a non-uniform skin colour or hyperpigmentation in the test area - Participants with a medical history of dysplastic nevi or melanoma - Participants with one of the following illnesses that might require regular systemic medication: Insulin-dependent diabetes, cancer - Participants with asthma, unless medicated - Participants with an electronic implant (e.g. pace maker, insulin pump, hearing aid) that cannot be removed during irradiation - AIDS (acquired immune deficiency syndrome) and infectious hepatitis, if known to the participants - Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients - Known allergy to latex - Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days prior to screening - Participation in another clinical study involving UV exposure to the same test site up to 2 months prior to screening - Previous participation in this study - Recent history (within the last 5 years) of alcohol or other substance abuse - Participants who have used a tanning bed or other tanning treatment on the back area up to 1 month prior to screening - Participants accustomed to using tanning beds - Participants who have used self-tanning products on the back area in the previous 1 month prior to screening - An employee of the sponsor or the study site or members of their immediate family |
Country | Name | City | State |
---|---|---|---|
Germany | GSK Investigational Site | Schenefeld | Schleswig-Holstein |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values | Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection. | Up to 24 hours post UV exposure | |
Secondary | Spectrum of Sun Protection | Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection. | Up to 30 minutes post UV exposure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02779270 -
Test the Outdoor Usage for Sunscreen Products in Female Adults
|
N/A | |
Completed |
NCT02936544 -
Sun Protection Factor Assay (SPF Assay 204/2016)
|
N/A | |
Completed |
NCT02936583 -
Sun Protection Factor Assay (SPF Assay 207/2016)
|
N/A | |
Completed |
NCT02936557 -
Sun Protection Factor Assay (SPF Assay 205/2016)
|
N/A | |
Completed |
NCT02936570 -
Sun Protection Factor Assay (SPF Assay 206/2016)
|
N/A | |
Completed |
NCT05085327 -
Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products
|
N/A | |
Completed |
NCT02760563 -
18611 - Sun Protection Factor Assay
|
N/A | |
Completed |
NCT02930798 -
Sun Protection Factor Assay (SPF Assay 203/2016)
|
N/A | |
Completed |
NCT02760576 -
18612 - Sun Protection Factor Assay
|
N/A | |
Completed |
NCT02854137 -
Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes
|
N/A | |
Completed |
NCT02930759 -
Sun Protection Factor Assay (SPF Assay 200/2016)
|
N/A | |
Completed |
NCT02930746 -
Sun Protection Factor Assay (SPF Assay 199/2016)
|
N/A | |
Completed |
NCT02930772 -
Sun Protection Factor Assay (SPF Assay 201/2016)
|
N/A | |
Completed |
NCT02930785 -
Sun Protection Factor Assay (SPF Assay 202/2016)
|
N/A | |
Completed |
NCT05109104 -
Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
|
N/A | |
Completed |
NCT04355286 -
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
|
Phase 1 | |
Completed |
NCT02962869 -
Human Photoallergy Test (824/2016)
|
N/A | |
Completed |
NCT02823496 -
18349-Human Photoallergy Test
|
N/A | |
Completed |
NCT02823483 -
18348-Human Phototoxicity Test
|
N/A | |
Completed |
NCT02962856 -
Human Phototoxicity Test (823/2016)
|
N/A |